Manhattan Pharmaceuticals, Inc., specializes in packaging bulk drugs in standard dosages for local hospitals. Wyant Memorial Hospital has asked Manhattan Pharmaceuticals to bid on the packaging of three million doses of medication at total cost plus a return on total cost of no more than 15 percent. Wyant defines total cost as including all variable costs of performing the service, a reasonable amount of fixed overhead, and reasonable administrative costs. The hospital will supply all packaging materials and ingredients. Wyant's administrator has indicated that any bid over $0.04 per dose will be rejected. The controller for Manhattan Pharmaceuticals has accumulated the following data prior to the preparation of the bid. Direct labor Variable overhead Fixed overhead Incremental administrative costs Production rate $ 21.00, per direct-labor hour (DLH) $ 17.00 per DLH $25.00 per DLH $2,500 for the order 6,000 doses per DLH Problem 15-40 Part 1 Required: 1. Calculate the minimum price per dose that Manhattan Pharmaceuticals could bid for the Wyant Memorial Hospital job that would not reduce the pharmaceutical company's income. (Round your answer to 4 decimal places.) Minimum price per dose 2. Calculate the bid price per dose using total cost and the maximum allowable return specified by Wyant Memorial Hospital. (Round your answer to 4 decimal places.) Bid price per dose 3. Independent of your answer to part (2), suppose that the price per dose that Manhattan Pharmaceuticals, Inc., calculated using the cost-plus criterion specified by Wyant Memorial Hospital is greater than the maximum bid of $0.04 per dose allowed by Wyant. Discuss the factors that the pharmaceutical company's management should consider before deciding whether or not to submit a bid at the maximum price of $0.04 per dose that Wyant allows. (Select all that apply.) Whether the maximum bid of $0.04 contributes toward covering fixed costs. Fixed overhead already incurred. Whether there are available jobs on which earnings might be greater. Whether Manhattan Pharmaceuticals has excess capacity